Faron Pharmaceuticals Oy
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FPHAF research report →
Companywww.faron.com
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
- CEO
- Markku Tapani Jalkanen
- IPO
- 2020
- Employees
- 40
- HQ
- Turku, FI
Price Chart
Valuation
- Market Cap
- $209.54M
- P/E
- -6.76
- P/S
- 0.00
- P/B
- -2.86
- EV/EBITDA
- -8.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 45.13%
- ROIC
- -96.14%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,920 · 99.92%
- EPS
- $-0.00 · 99.91%
- Op Income
- $-18,673
- FCF YoY
- 3.06%
Performance & Tape
- 52W High
- $3.30
- 52W Low
- $3.30
- 50D MA
- $3.30
- 200D MA
- $3.30
- Beta
- 0.18
- Avg Volume
- 0
Get TickerSpark's AI analysis on FPHAF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FPHAF Coverage
We haven't published any research on FPHAF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FPHAF Report →